Perspective Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Perspective Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Jun 2022Jun 2021Jun 2020Jun 2019Jun 2018
Revenue & Gross Profit
Revenue0.001.435.4210.059.687.315.92
Cost of Revenue0.0020.343.054.934.564.274.08
Gross Profit0.00-18.912.375.125.123.051.84
Operating Expenses
Research & Development41.640.970.851.43-1.13-1.471.75
Selling, General & Administrative26.6121.065.577.137.556.856.83
Operating Expenses92.3422.036.428.578.608.308.57
Operating Income10.46-40.94-6.42-3.45-3.48-5.25-6.73
Other Income/Expense
Interest Income10.520.930.120.060.000.000.03
Interest Expense-0.05-0.080.000.000.000.000.00
Other Income/Expense-91.84-0.02-2.130.010.03-0.030.00
Income
Income Before Tax-81.38-40.11-6.30-3.39-1.34-2.20-6.70
Income Tax Expense-2.10-2.65-0.030.000.000.000.00
Net Income-79.28-46.51-7.27-3.39-3.45-5.14-6.70
Net Income - Continuous Operations-79.28-37.46-7.27-3.390.000.000.00
Net Income - Discontinued Operations-0.95-9.050.000.000.000.000.00
EBITDA10.46-40.23-6.14-3.29-3.33-2.01-6.60
EBIT-80.43-40.94-6.42-3.44-3.48-2.20-6.73
Depreciation & Amortization0.000.710.280.150.150.140.00
Earnings Per Share
Basic EPS-1.00-2.00-1.00----
Diluted EPS-1.00-2.00-1.00----
Basic Shares Outstanding64.4326.7614.20103.8467.6067.0455.16
Diluted Shares Outstanding64.4326.7614.20103.8467.6067.0455.16